In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey

Basit Öğe Kaydı
dc.authoridKARABAY, OGUZ/0000-0003-1514-1685
dc.authoridKARAALI, Ridvan/0000-0003-2440-7529
dc.authoridYILDIZ, ILKNUR ESEN/0000-0003-2987-0483
dc.authoridYildiz Kaya, Sibel/0000-0002-6319-7889
dc.authoridhizel, kenan/0000-0001-8644-139X
dc.authoridErben, Nurettin/0000-0003-0373-0132
dc.contributor.authorYildirim, Figen Sarigul
dc.contributor.authorUser, Ulku
dc.contributor.authorSari, Nagehan Didem
dc.contributor.authorKurtaran, Behice
dc.contributor.authorOnlen, Yusuf
dc.contributor.authorSenates, Ebubekir
dc.contributor.authorGunduz, Alper
dc.date.accessioned2024-09-18T20:16:34Z
dc.date.available2024-09-18T20:16:34Z
dc.date.issued2022
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractBackground: People who inject drugs (PWID) should be treated in order to eliminate hepatitis C virus in the world. The aim of this study was to compare direct-acting antivirals treatment of hepatitis C virus for PWID and non-PWID in a real-life setting. Methods: We performed a prospective, non-randomized, observational multicenter cohort study in 37 centers. All patients treated with direct-acting antivirals between April 1, 2017, and February 28, 2019, were included. In total, 2713 patients were included in the study among which 250 were PWID and 2463 were non-PWID. Besides patient characteristics, treatment response, follow-up, and side effects of treatment were also analyzed. Results: Genotype 1a and 3 were more prevalent in PWID-infected patients (20.4% vs 9.9% and 46.8% vs 5.3%). The number of naive patients was higher in PWID (90.7% vs 60.0%), while the number of patients with cirrhosis was higher in non-PWID (14.1% vs 3.7%). The loss of follow-up was higher in PWID (29.6% vs 13.6%). There was no difference in the sustained virologic response at 12 weeks after treatment (98.3% vs 98.4%), but the end of treatment response was lower in PWID (96.2% vs 99.0%). In addition, the rate of treatment completion was lower in PWID (74% vs 94.4%). Conclusion: Direct-acting antivirals were safe and effective in PWID. Primary measures should be taken to prevent the loss of follow-up and poor adherence in PWID patients in order to achieve World Health Organization's objective of eliminating viral hepatitis.en_US
dc.identifier.doi10.5152/tjg.2022.21834
dc.identifier.endpage978en_US
dc.identifier.issn2148-5607
dc.identifier.issue11en_US
dc.identifier.pmid36415900en_US
dc.identifier.scopus2-s2.0-85142524509en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage971en_US
dc.identifier.trdizinid1175267en_US
dc.identifier.urihttps://doi.org/10.5152/tjg.2022.21834
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1175267
dc.identifier.urihttps://hdl.handle.net/20.500.12483/9599
dc.identifier.volume33en_US
dc.identifier.wosWOS:000898674900009en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofTurkish Journal of Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDrug therapyen_US
dc.subjectdrug usersen_US
dc.subjecthepatitis C virusen_US
dc.titleIn a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
2.15 MB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu